It has been announced that NuVasive has recieved the Japanese approval of the CoRoent Large Impacted and the CoRoent Large Tapered titanium alloy implants. The implants are used in posterior spine fusion procedures and are NuVasive’s first two interbody fusion cages to be approved in Japan. The approvals allow the company to participate in the world’s second largest spine market with cervical solutions and comprehensive posterior products, which have already been cleared for use.
Alex Lukianov, chairman and CEO of NuVasive, said: “This is an exciting stepping stone for NuVasive. For several years, we have been thoughtfully laying the groundwork and making the investments to support a direct operation in Japan, a market estimated to be close to US$400 million in size. We are proud to see all of those efforts coming to fruition so that our revenue ramp can begin in earnest at the start of the first quarter. We look forward to the opportunity to introduce Japanese surgeons and patients to NuVasive; first to our game changing portfolio of cervical and posterior thoraco-lumbar solutions, and then, upon further regulatory approval, to our unique lateral XLIFsolution.”